The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

While the Japanese employee of Astellas Pharma was indicted in August last year, the Chinese side has not disclosed details ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Veeva Systems VEEV is making smart moves in 2025 by expanding its network of high-impact partnerships, helping the company ...

Good morning, we have news of a big M&A deal this morning. Let’s get into it. Merck said this moring that it will buy Verona ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

CYP17A1 Inhibitors Market to Reach USD 1.35 Billion by 2025, Fueled by Advancements in Prostate Cancer Therapeutics The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...